Rating Change
Rothschild & Co analysts initiated coverage on ResMed Inc. (NYSE:RMD) with a rating of Neutral on August 19, 2026.
new coverageNYSE:RMD
Rothschild & Co Initiates Coverage on ResMed Inc. (RMD) with Neutral
Rothschild & Co analysts initiated coverage on ResMed Inc. (NYSE:RMD) with a rating of Neutral on August 19, 2026.
At publication ·
What changed
ResMed Inc. (NYSE:RMD) · new coverage
- Firm
- Rothschild & Co
- Rating
- Neutral
- Price at event
- $230.65
- Market capitalization
- $37.0B
At a glance
Key takeaways
- Rothschild & Co initiated coverage of ResMed Inc. (RMD) with a Neutral rating on August 19, 2026, as the stock trades at $230.65 with a $37.0 billion market capitalization.
Market Context
ResMed Inc. operates in the Healthcare sector. The stock currently trades at $230.65 with a market capitalization of $37.0B. The stock has declined 9.8% over the past 52 weeks.
Analyst coverage from Rothschild & Co provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for ResMed Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for ResMed Inc.
Among the 10 most recent ratings: 3 Buy, 7 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 19, 2026 | Rothschild & Co | Neutral | N/A |
| Aug 07, 2026 | Wells Fargo | Equal-Weight | N/A |
| Aug 07, 2026 | Keybanc | Overweight | N/A |
| Aug 07, 2026 | RBC Capital | Sector Perform | N/A |
| Aug 07, 2026 | Piper Sandler | Neutral | N/A |
Related Tools: Analyst Ratings Dashboard | View RMD Stock Page
Frequently Asked Questions
What does the Neutral rating mean for RMD?
A rating of Neutral from Rothschild & Co reflects the analyst's outlook on ResMed Inc. (NYSE:RMD). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the RMD forecast page.
